Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Microbot Medical Inc.

Ticker
MBOT
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight ongoing commercialization efforts, including securing distribution agreements and initial customers, alongside continued financial losses reported in quarterly results.

Recent developments:
  • Microbot Medical Inc. reported a Q3 2026 loss and revenue below expectations [N1].
  • The company secured its first office-based lab customer for the LIBERTY Endovascular Robotic System in October 2026 [N2].
  • Microbot Medical signed a three-year distribution deal for LIBERTY in Israel in October 2026 [N3].
  • The company reported Q2 2026 loss and revenue below expectations [N4].
  • Microbot Medical reported Q1 2026 loss and revenue below expectations [N5].
  • Microbot Medical began full U.S. launch of the LIBERTY system in April 2026 [N15].
Overview

Microbot Medical Inc. develops and commercializes the LIBERTY® Endovascular Robotic Surgical System, a medical device intended for minimally invasive endovascular procedures. The company shifted focus from research and development to commercialization in 2025. It relies on third-party manufacturers for production and has limited commercial operating history. Microbot Medical has secured patents globally to protect its technology and has begun commercial launch activities including distribution agreements and initial customer acquisitions. The company has reported operating losses and limited revenues to date, reflecting the early stage of commercialization. It maintains a strong liquidity position as of Q3 2026 but anticipates ongoing capital needs to support sales, marketing, manufacturing scale-up, and regulatory compliance.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Microbot Medical Inc. is a commercial-stage medical device company focused on the LIBERTY® Endovascular Robotic Surgical System. The company has transitioned from R&D to commercialization primarily in 2025 and has begun full U.S. launch activities. It has secured distribution agreements and initial customers internationally. Despite these efforts, Microbot Medical has reported continuing operating losses and revenue below expectations in 2026 quarters. As of September 30, 2026, the company maintains a strong liquidity position with approximately $66.87 million in current assets and a current ratio of 15.7. The company faces risks related to manufacturing scale-up, market acceptance, reimbursement, regulatory approvals, and the need for additional capital to sustain operations and growth [S1][S2][N1][N2][N3].

Scenarios for MBOT

Bull case model:

Microbot Medical's commercialization of the LIBERTY® system includes progress in market penetration through patent portfolio expansion and initial distribution agreements, such as a three-year deal in Israel and first office-based lab customer. The company maintains strong liquidity as of Q3 2026, supporting ongoing commercialization efforts. Scaling manufacturing efficiently, securing reimbursement, and gaining clinical acceptance are key factors for building a sustainable business model.

Bear case model:

Microbot Medical faces significant risks including continued operating losses, limited commercial operating history, and uncertainty around manufacturing scale-up and market acceptance. The company has not yet generated significant revenues and has reported revenue shortfalls in recent quarters. Reimbursement uncertainties, regulatory hurdles, and competition pose challenges. The need for additional capital to sustain operations creates dilution risk and potential operational constraints. Failure to achieve timely commercialization or profitability could materially harm the business.

Moat:

Microbot Medical's moat is primarily based on its proprietary technology embodied in the LIBERTY® Endovascular Robotic Surgical System, supported by a global patent portfolio of 45 issued patents. The company's focus on robotic endovascular surgery targets a specialized medical device market with high barriers to entry due to regulatory requirements, technological complexity, and the need for clinical acceptance. However, the company faces competition from established medical device manufacturers and emerging technologies. Its moat depends on successful commercialization, manufacturing scale-up, intellectual property protection, and acceptance by medical professionals and payors.

Risks overview
Risks summary
The biggest risks for Microbot Medical relate to its ability to successfully commercialize the LIBERTY® system amid operational, financial, regulatory, and market acceptance challenges.
Risks details:

• Commercialization Risk: Microbot Medical depends heavily on successful commercialization of the LIBERTY® system. Delays or failure to establish manufacturing, sales, marketing, and distribution capabilities could materially harm the business [S1].
• Financial Risk: The company has incurred significant operating losses and expects to continue incurring losses. It requires additional capital to sustain operations and commercialization efforts. Failure to raise capital could force delays or reductions in programs [S1].
• Market Acceptance and Reimbursement Risk: Acceptance by medical professionals, institutions, and payors is uncertain. Inadequate reimbursement or lack of perceived clinical advantages could limit sales growth [S1].
• Regulatory Risk: Obtaining and maintaining regulatory clearances and approvals is complex and uncertain. Unfavorable clinical trial results or delays could adversely affect prospects [S1].
• Manufacturing Risk: Limited experience in commercial-scale manufacturing and reliance on third-party manufacturers pose risks to production quality, cost, and schedule [S1].
• Competitive Risk: Competition from existing and emerging medical device technologies could limit market penetration and pricing power [S1].

FINAL FORECAST FOR MBOT

Final take one line
Microbot Medical is a commercial-stage medical device company with detailed disclosures on its LIBERTY® system commercialization, financial losses, and operational risks, supported by strong liquidity as of Q3 2026.
Final take 12 to 24 month view

Business trends: Continued commercialization of the LIBERTY® Endovascular Robotic Surgical System with initial customer acquisitions and distribution agreements.
Execution milestones: Scaling manufacturing capabilities, expanding sales and marketing efforts, and securing regulatory approvals and reimbursement.
Key risks: Sustained operating losses, capital needs, market acceptance challenges, manufacturing scale-up, and regulatory uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Microbot Medical Inc. is a commercial-stage medical device company focused on the LIBERTY® Endovascular Robotic Surgical System as its sole product.
  • The company shifted primarily from research and development to commercialization of LIBERTY® in 2025.
  • Microbot Medical has limited operating history as a commercial-stage company and has not recognized significant revenues through December 31, 2025.
  • The company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future due to ongoing sales, marketing, research, development, and regulatory activities [S1].
  • Microbot Medical depends heavily on the successful commercialization of the LIBERTY® system and faces risks related to manufacturing scale-up, sales and marketing capabilities, intellectual property protection, market acceptance, and reimbursement [S1].
  • The company intends to manufacture products through third-party manufacturers and has limited experience in manufacturing at commercial scale [S1].
  • Microbot Medical has secured a three-year distribution deal for LIBERTY® in Israel and has secured its first office-based lab customer for the system [N3][N2].
  • The company began a full U.S. launch of the LIBERTY® system in April 2026 [N15].
  • Recent quarterly reports show continuing losses and revenue below expectations for Q1, Q2, and Q3 2026 [N5][N4][N1].
  • As of September 30, 2026, Microbot Medical had cash and cash equivalents of approximately $2.29 million and short-term investments of about $59.54 million, with current assets totaling approximately $66.87 million and current liabilities of about $4.26 million, resulting in a strong current ratio of 15.7 and a cash ratio of 14.51 [S2].
  • The company has a global patent portfolio with 45 issued patents, including recent patents granted in Canada and China, supporting its intellectual property position [N25][N24].
  • Microbot Medical faces risks related to reimbursement uncertainties, regulatory approvals, market acceptance by medical professionals and institutions, and competition from existing and emerging technologies [S1].
  • The company has funded operations primarily through equity offerings and grants and anticipates the need for additional capital to continue commercialization and development efforts [S1].
  • Microbot Medical incurs substantial costs associated with operating as a public company in the United States [S1].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Microbot Medical Inc. (MBOT) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/microbot-medical-inc-mbot-reports-q3-loss-misses-revenue-estimates
  • N2 | 2026-10-27 | www.nasdaq.com | Microbot Medical Inc. Secures First Office-Based Lab Customer for LIBERTY Endovascular Robotic System | https://www.nasdaq.com/articles/microbot-medical-inc-secures-first-office-based-lab-customer-liberty-endovascular-robotic
  • N3 | 2026-10-06 | www.nasdaq.com | Microbot Medical Signs Three-Year Distribution Deal For LIBERTY In Israel | https://www.nasdaq.com/articles/microbot-medical-signs-three-year-distribution-deal-liberty-israel
  • N4 | 2026-08-11 | www.nasdaq.com | Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/microbot-medical-inc-mbot-reports-q2-loss-lags-revenue-estimates
  • N5 | 2026-05-13 | www.nasdaq.com | Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/microbot-medical-inc-mbot-reports-q1-loss-misses-revenue-estimates
  • N6 | 2026-05-05 | www.nasdaq.com | Cencora to Report Q2 Earnings: What's in Store for the Stock? | https://www.nasdaq.com/articles/cencora-report-q2-earnings-whats-store-stock
  • N7 | 2026-05-04 | www.nasdaq.com | Solventum to Post Q1 Earnings: Is a Beat Likely for the Stock? | https://www.nasdaq.com/articles/solventum-post-q1-earnings-beat-likely-stock
  • N8 | 2026-05-04 | www.nasdaq.com | DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock? | https://www.nasdaq.com/articles/dentsply-sirona-post-q1-earnings-whats-store-stock
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine